Stockscreener 앱 받기
9.57
0.42%
0.04
시간 외 거래:
9.57
전일 마감가:
$9.53
열려 있는:
$9.52
하루 거래량:
153.98K
Relative Volume:
1.09
시가총액:
$203.73M
수익:
$73.62M
순이익/손실:
$-138.24M
주가수익비율:
-1.516
EPS:
-6.3125
순현금흐름:
$-99.19M
1주 성능:
-11.96%
1개월 성능:
-24.23%
6개월 성능:
-21.10%
1년 성능:
+4.82%
1일 변동 폭
$9.36
$9.65
1주일 범위
$9.36
$11.01
52주 변동 폭
$8.51
$17.80
Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile
명칭
Enanta Pharmaceuticals Inc
전화
617 607 0800
주소
500 ARSENAL STREET, WATERTOWN, MA
ENTA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| ENTA | 9.57 | 203.73M | 73.62M | -138.24M | -99.19M | -6.3125 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-12-09 | 개시 | H.C. Wainwright | Buy |
| 2022-07-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2022-06-01 | 업그레이드 | Evercore ISI | Underperform → In-line |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-09-09 | 개시 | SVB Leerink | Mkt Perform |
| 2021-01-29 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2020-11-24 | 개시 | Evercore ISI | Underperform |
| 2020-08-28 | 재개 | ROTH Capital | Buy |
| 2020-08-26 | 개시 | Piper Sandler | Overweight |
| 2020-07-27 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2020-03-17 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2019-11-22 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-26 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2019-05-24 | 개시 | Wolfe Research | Outperform |
| 2019-04-23 | 업그레이드 | Berenberg | Hold → Buy |
| 2018-12-13 | 개시 | Berenberg | Hold |
| 2018-06-06 | 개시 | ROTH Capital | Buy |
| 2018-02-08 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-01-02 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2017-11-21 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2017-07-11 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2016-04-28 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | 재확인 | Barclays | Underweight |
| 2015-10-23 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2015-10-23 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
모두보기
Enanta Pharmaceuticals Inc 주식(ENTA)의 최신 뉴스
Head to Head Analysis: CannTrust (OTCMKTS:CNTTF) vs. Enanta Pharmaceuticals (NASDAQ:ENTA) - Defense World
ARMISTICE CAPITAL, LLC Adjusts Stake in Enanta Pharmaceuticals I - GuruFocus.com
Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Price Passes Below 200-Day Moving AverageWhat's Next? - MarketBeat
(ENTA) Proactive Strategies - Stock Traders Daily
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Urticaria Clinical Trial Pipeline Accelerates: 20+ Leading Companies Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.
Assenagon Asset Management S.A. Trims Position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - MarketBeat
(ENTA) On The My Stocks Page - Stock Traders Daily
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Short Interest Up 14.7% in October - MarketBeat
The past three years for Enanta Pharmaceuticals (NASDAQ:ENTA) investors has not been profitable - Yahoo Finance
Enanta Pharmaceuticals' SWOT analysis: RSV pipeline progress boosts stock outlook - Investing.com
Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Price Passes Below Two Hundred Day Moving Average – Here’s What Happened - Defense World
Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Price Passes Below Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Where are the Opportunities in (ENTA) - Stock Traders Daily
Enanta Pharmaceuticals (ENTA): Promising Clinical Stage Biotech with Robust Pipeline - Insider Monkey
Millennium Management LLC's Strategic Acquisition of Enanta Pharmaceuticals Shares - Yahoo Finance
Millennium Management LLC's Strategic Acquisition of Enanta Phar - GuruFocus.com
AQR Capital Management LLC Cuts Stock Position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - MarketBeat
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Sold by Dimensional Fund Advisors LP - MarketBeat
Analysts Set Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) PT at $20.00 - MarketBeat
Trend Tracker for (ENTA) - Stock Traders Daily
Enanta shares reiterates Buy rating on RSV drug results By Investing.com - Investing.com Canada
Primary Biliary Cholangitis Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Intercept Pharma, Enanta Pharma, COUR Pharma, Novartis, Gannex Pharma, Nanjing Chia-tai - The Globe and Mail
HC Wainwright Reiterates Buy Rating for Enanta Pharmaceuticals (NASDAQ:ENTA) - MarketBeat
A Glimpse Into The Expert Outlook On Enanta Pharma Through 4 Analysts - Benzinga
JMP Securities Reiterates "Market Outperform" Rating for Enanta Pharmaceuticals (NASDAQ:ENTA) - MarketBeat
Enanta stock holds market outperform rating despite Pfizer drug halt By Investing.com - Investing.com Canada
Sei Investments Co. Sells 15,230 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Defense World
Will Enanta Pharma Breathe Easy? - RTTNews
Health Check: How Prudently Does Enanta Pharmaceuticals (NASDAQ:ENTA) Use Debt? - Simply Wall St
Enanta Pharmaceuticals (ENTA) Surges 5.6%: Is This an Indication of Further Gains? - MSN
American Century Companies Inc. Boosts Stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Defense World
Enanta shares hold as Baird affirms target on new data By Investing.com - Investing.com Canada
Enanta’s Phase II Challenge Data Position A Second Potential RSV Therapy - Scrip
Enanta Pharmaceuticals (NASDAQ:ENTA) Rating Reiterated by JMP Securities - MarketBeat
Rhumbline Advisers Increases Position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Defense World
Enanta’s next RSV pill raises ‘high bar set by zelicapavir’ - The Pharma Letter
Enanta reports promising results for RSV drug EDP-323 - Investing.com
Enanta Pharmaceuticals Reports Antiviral For Respiratory Syncytial Virus Reduces Virus Levels, Symptoms In Study - Benzinga
Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With Respiratory Syncytial Virus (RSV) - BioSpace
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Sold by Armistice Capital LLC - MarketBeat
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Bought by Bank of New York Mellon Corp - Defense World
Enanta Pharmaceuticals Inc [ENTA] Chief Medical Officer makes an insider sale of 5,375 shares worth 91,805. - Knox Daily
Is Enanta Pharmaceuticals Inc (ENTA) a good investment opportunity? - US Post News
Gaining Ground: Enanta Pharmaceuticals Inc (ENTA) Closes Lower at 11.30, Down -0.79 - The Dwinnex
(ENTA) Investment Analysis - Stock Traders Daily
Envestnet (NYSE:ENV) Earns "Neutral" Rating from DA Davidson - MarketBeat
Rhumbline Advisers Raises Stock Holdings in Enovix Co. (NASDAQ:ENVX) - Defense World
Enel Chile (NYSE:ENIC) Trading Down 2.6% - MarketBeat
Smart Money Is Betting Big In ENVX Options - Benzinga
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Enanta Pharmaceuticals Inc (ENTA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.66%
1.11%
자본화:
|
볼륨(24시간):